DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for exostosis — screening already-approved drugs against its 35-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleExostosis maps to a 35-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for exostosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
SET and MYND domain containing 3 (SMYD3) — SMYD3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet samdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6P7Z · 1.19 Å · ligand S-ADENOSYLMETHIONINE (SAM). Experimental structure, not a prediction.
What the evidence adds up to
Hereditary multiple exostoses (HME) is caused by mutations in the HS-synthesising enzymes EXT1 and EXT2, leading to heparan sulfate deficiency. The exostoses are benign cartilaginous-bony outgrowths that form next to growth plates, can cause growth retardation and deformities, chronic pain and impaired motion, and progress to malignancy in 2-5% of patients. Aberrant distribution of signalling factors combined with aberrant responsiveness of target cells to those same factors appears to be a major culprit in exostosis formation. Insights from studies of signalling protein distribution and activity in wild-type and HS-deficient cells and tissues suggest plausible ideas about how HME could be treated in the future, but no specific drug or intervention is tested in this review.
In a study of 11 exostosis chondrocyte strains, diminished levels of EXT1 protein were found in 9 (82%) and EXT2 protein in 5 (45%); 4 (36%) were deficient in both. Mutational analysis alone did not predict all observed decreases in EXT gene products, suggesting additional genetic mutations. In one isolated non-HME exostosis, three genetic hits were detected: deletion of one EXT1 gene, a net 21-bp deletion within the other EXT1 gene, and a deletion in intron 1 causing loss of gene product. Exostosis chondrocytes also exhibited an unusual cellular phenotype characterised by abnormal actin bundles in the cytoplasm, suggesting EXT genes play a role in chondrocyte cytoskeleton regulation.
A retrospective study of 65 Caucasian patients treated surgically for symptomatic solitary exostosis from March 2004 to Jan 2011 reported that the most frequent symptom was pain, with other complaints including nervous compression, aesthetic injury, and reduced range of motion. No major surgical complications were found, the rate of disease recurrence was null, and a small group of patients referred persisting pain in the lesion area during two years of follow-up. The authors concluded that surgical treatment of "strategic exostosis" is safe and allows elimination of symptoms with low complication rates.
What is still missing is any drug therapy tested in human patients for HME or solitary exostosis. The molecular understanding of EXT mutations and heparan sulfate deficiency has not yet produced a clinical trial. No repurposed drug has been evaluated for this condition. Surgical resection remains the only intervention with published outcome data, and no stratification of patients by genetic subtype or molecular marker has been attempted in a treatment study.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Developmental Dynamics · 2013 · 71 citations · open access
Heparan sulfate in skeletal development, growth, and pathology: The case of hereditary multiple exostoses
AbstractHeparan sulfate (HS) is an essential component of cell surface and matrix-associated proteoglycans. Due to their sulfation patterns, the HS chains interact with numerous signaling proteins and regulate their distribution and activity on target cells. Many of these proteins, including bone morphogenetic protein family members, are expressed in the growth plate of developing skeletal elements, and several skeletal phenotypes are caused by mutations in those proteins as well as in HS-synthesizing and modifying enzymes. The disease we discuss here is hereditary multiple exostoses (HME), a disorder caused by mutations in HS synthesizing enzymes EXT1 and EXT2, leading to HS deficiency. The exostoses are benign cartilaginous-bony outgrowths, form next to growth plates, can cause growth retardation and deformities, chronic pain and impaired motion, and progress to malignancy in 2-5% of patients. We describe recent advancements on HME pathogenesis and exostosis formation deriving from studies that have determined distribution, activities and roles of signaling proteins in wild-type and HS-deficient cells and tissues. Aberrant distribution of signaling factors combined with aberrant responsiveness of target cells to those same factors appear to be a major culprit in exostosis formation. Insights from these studies suggest plausible and cogent ideas about how HME could be treated in the future.
Cell Motility and the Cytoskeleton · 2001 · 61 citations
Diminished levels of the putative tumor suppressor proteins EXT1 and EXT2 in exostosis chondrocytes
AbstractThe EXT family of putative tumor suppressor genes affect endochondral bone growth, and mutations in EXT1 and EXT2 genes cause the autosomal dominant disorder Hereditary Multiple Exostoses (HME). Loss of heterozygosity (LOH) of these genes plays a role in the development of exostoses and chondrosarcomas. In this study, we characterized EXT genes in 11 exostosis chondrocyte strains using LOH and mutational analyses. We also determined subcellular localization and quantitation of EXT1 and EXT2 proteins by immunocytochemistry using antibodies raised against unique peptide epitopes. In an isolated non-HME exostosis, we detected three genetic hits: deletion of one EXT1 gene, a net 21-bp deletion within the other EXT1 gene and a deletion in intron 1 causing loss of gene product. Diminished levels of EXT1 and EXT2 protein were found in 9 (82%) and 5 (45%) exostosis chondrocyte strains, respectively, and 4 (36%) were deficient in levels of both proteins. Although we found mutations in exostosis chondrocytes, mutational analysis alone did not predict all the observed decreases in EXT gene products in exostosis chondrocytes, suggesting additional genetic mutations. Moreover, exostosis chondrocytes exhibit an unusual cellular phenotype characterized by abnormal actin bundles in the cytoplasm. These results suggest that multiple mutational steps are involved in exostosis development and that EXT genes play a role in cell signaling related to chondrocyte cytoskeleton regulation.
[Surgical treatment of osteochondromas: indication in "Strategic Exostosis"].
AbstractOBJECTIVE: The osteochondromas represents is the most frequent benign lesion interesting the bone tissue. This lesion, often asymptomatic, can arise through mechanical, irritative or painful syndromes: "strategic exostosis". MATERIALS AND METHODS: In our present study we retrospectively evaluated 65 Caucasian patients, which have been treated surgically for symptomatic solitary exostosis from March 2004 to Jan 2011. The most frequent symptom referred by patient has been represented by pain. The others complains were related to nervous compression, esthetic injury and a reduction of range of motion. By using the VAS score we evaluated the post-operative bone pain at 3, 12 and 24 months. At the end of follow up we evaluated by a validated questionnaire the grade of patient satisfaction. RESULTS: No major surgical complication were found. The rate of disease recidivism was null. Only a small group of patient referred a persisting pain in the lesion area during the two years follow up. In this subgroup the rate of satisfaction was obviously reduced. CONCLUSIONS: In our opinion the surgical treatment of strategic exostosis, is safe and it should be recommended, since it allows to eliminate the noise with a low incidence of complications. The large majority of out patients were satisfied of the clinical improvement they experienced.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
